Cancer Gene Therapy:BMP1过表达反应了透明细胞肾细胞肿瘤的不良预后

2019-06-15 AlexYang MedSci原创

透明细胞肾细胞癌(ccRCC)具有最高的致死率、侵入性和转移性的肾细胞癌亚型。骨形态生成蛋白(BMP)家族在多种癌症的致病机理中具有相关性。目前,关于BMPs在ccRCC中的预测作用所知甚少。最近,有研究人员筛选了癌症基因组图谱肾透明细胞肿瘤(TCGA-KIRC)数据库,筛选的目标数据是具有完整临床信息和BMP家族表达数据的ccRCC患者数据。多变量分析表明了BMP1的高表达与更短的总生存(OS)

透明细胞肾细胞癌(ccRCC)是具有最高的致死率、侵入性和转移性的肾细胞癌亚型。骨形态生成蛋白(BMP)家族在多种癌症的致病机理中具有相关性。目前,关于BMPs在ccRCC中的预测作用所知甚少。

最近,有研究人员筛选了癌症基因组图谱肾透明细胞肿瘤(TCGA-KIRC)数据库,筛选的目标数据是具有完整临床信息和BMP家族表达数据的ccRCC患者数据。多变量分析表明了BMP1的高表达与更短的总生存(OS)(p=0.001)和更短的无疾病生存(DFS)(p=0.018)相关。基因集合富集分析(GSEA)表明了BMP1与上皮-间质转化(EMT)、G2M检查点、血管生成、缺氧途径和Kirsten大鼠肉瘤病毒癌基因(KRAS)信号转导相关。另外,BMP1的敲除能够在体内和体外抑制ccRCC的恶性程度。

最后,研究人员指出,他们的结果表明了BMP1的高表达是不良的预后因子,并且基因治疗可以作为ccRCC有效治疗方法。

原始出处:

Wen Xiao, Xuegang Wang, Tao Wang et al. Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma. Cancer Gene Therapy. 03 Jun 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680027, encodeId=082e168002e01, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Sun Jan 12 10:14:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958197, encodeId=d937195819e67, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Nov 22 01:14:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634078, encodeId=5a6d16340e8af, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Sat Sep 14 20:14:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049190, encodeId=ee412049190ef, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738958, encodeId=cb721e38958a0, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Nov 11 12:14:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336388, encodeId=f3cf13363887e, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Mon Jun 17 05:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680027, encodeId=082e168002e01, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Sun Jan 12 10:14:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958197, encodeId=d937195819e67, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Nov 22 01:14:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634078, encodeId=5a6d16340e8af, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Sat Sep 14 20:14:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049190, encodeId=ee412049190ef, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738958, encodeId=cb721e38958a0, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Nov 11 12:14:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336388, encodeId=f3cf13363887e, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Mon Jun 17 05:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2019-11-22 lq1767
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680027, encodeId=082e168002e01, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Sun Jan 12 10:14:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958197, encodeId=d937195819e67, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Nov 22 01:14:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634078, encodeId=5a6d16340e8af, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Sat Sep 14 20:14:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049190, encodeId=ee412049190ef, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738958, encodeId=cb721e38958a0, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Nov 11 12:14:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336388, encodeId=f3cf13363887e, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Mon Jun 17 05:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2019-09-14 HNYYM
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680027, encodeId=082e168002e01, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Sun Jan 12 10:14:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958197, encodeId=d937195819e67, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Nov 22 01:14:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634078, encodeId=5a6d16340e8af, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Sat Sep 14 20:14:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049190, encodeId=ee412049190ef, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738958, encodeId=cb721e38958a0, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Nov 11 12:14:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336388, encodeId=f3cf13363887e, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Mon Jun 17 05:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
    2020-03-24 cy0324
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680027, encodeId=082e168002e01, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Sun Jan 12 10:14:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958197, encodeId=d937195819e67, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Nov 22 01:14:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634078, encodeId=5a6d16340e8af, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Sat Sep 14 20:14:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049190, encodeId=ee412049190ef, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738958, encodeId=cb721e38958a0, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Nov 11 12:14:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336388, encodeId=f3cf13363887e, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Mon Jun 17 05:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1680027, encodeId=082e168002e01, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Sun Jan 12 10:14:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958197, encodeId=d937195819e67, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Nov 22 01:14:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634078, encodeId=5a6d16340e8af, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Sat Sep 14 20:14:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049190, encodeId=ee412049190ef, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738958, encodeId=cb721e38958a0, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Nov 11 12:14:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336388, encodeId=f3cf13363887e, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Mon Jun 17 05:14:00 CST 2019, time=2019-06-17, status=1, ipAttribution=)]

相关资讯

Oncogene:UHRF1能够通过对TXNIP的表观调控促进肾细胞癌的恶化

UHRF1是一个重要的表观遗传调控因子,且属于UHRF家族。UHRF1的过表达在许多类肿瘤中存在,并且其过表达与某些癌症类型的不良预后和更短的生存相关。然而,其在肾细胞癌(RCC)中的功能仍旧不清楚。最近,有研究人员报道了RCC肿瘤组织比正常肾组织具有明显更高的UHRF1表达。siRNA或者shRNA引起的UHRF1表达的下调在RCC细胞系中能够导致细胞生存力减少、抑制细胞迁移和侵入,以及增加细胞

Cell Death & Disease:c-FLIP和CD95对肾细胞癌的生存是必需的

透明细胞肾细胞癌(ccRCC)是肾脏癌症中最突出的肿瘤。肾细胞癌(RCC)岁肿瘤治疗的抗性可以归结于抗凋亡蛋白的过表达而引起的细胞凋亡的抗性等。然而,在ccRCC中,关于细胞凋亡抑制因子c-FLIP的作用和它对死亡受体诱导的细胞凋亡的影响所知甚少。最近,有研究人员阐释了c-FLIP在4个ccRCC细胞系中对CD95L诱导的细胞凋亡抗性的产生非常关键。明显的是,shRNA对c-FLIP表达的下调作用

Sci Rep:转移性肾细胞癌负担和位点可作为一线药物舒尼替尼治疗效果的预测因子

最近,有研究人员调查了基线肿瘤负担和位点对一线肾癌治疗药物舒尼替尼治疗效果的预后影响。研究人员评估了基线和治疗中的CT扫描,并利用卡普兰-梅尔分析和威布尔生存估计模型描述了舒尼替尼治疗的响应。研究人员还利用逻辑回归来确定肿瘤位点、负担和生存之间的相关性。另外,研究人员还对治疗组和外部验证组进行了转移共同发生的贝叶斯推断分析。研究总共包括了100名具有转移性透明细胞肾细胞肿瘤且接受舒尼替尼治疗的患者

Nat Commun:GPX4依赖的癌细胞状态是透明细胞表型的基础并与细胞铁死亡有关

透明细胞肿瘤(CCCs)是一种高度恶性化的组织,通常起源于肾脏和卵巢。CCCs可以通过异常的脂糖原积累来区分,并且对很多抗癌疗法具有耐受性。最近, 有研究人员鉴定了固有的细胞铁死亡脆弱性与CCCs中独特的细胞代谢状态有关。该脆弱性超越了家系和遗传背景,并且可以通过利用细胞分子来抑制谷胱甘肽过氧化物酶(GPX4)来进行研究。研究人员利用CRISPR筛选和脂质体分析,研究人员鉴定了缺氧诱导因子(HIF

Cell Death & Disease:靶向转录因子LXR治疗透明细胞肾细胞癌研究

越来越多的证据表明透明细胞肾细胞癌(ccRCC)是一种代谢相关的疾病。脂肪酸(FA)和胆固醇代谢变化在ccRCC发展过程中具有重要的作用。肝X受体(LXR)是一个核转录因子受体,能够调控与FA合成和胆固醇转运相关的许多关键分子。因此,靶向LXR也许能够为ccRCC提供新的治疗靶标。然而,LXR在ccRCC中可能的调控作用和分子机制仍旧未知。最近,有研究人员发现,LXR激动剂和XLR反向激动剂能够抑

K药再拓疆土——细数晚期肾癌靶向治疗现状

近日,美国食品和药物管理局FDA批准Pembrolizumab (Keytruda,俗称K药)联合Inlyta(axitinib,阿昔替尼)用于晚期肾细胞癌(RCC)患者的一线治疗。Inlyta由辉瑞研发,是一种抑制血管内皮生长因子(VEGF)受体1、2、3的酪氨酸激酶抑制剂。Keytruda与Inlyta构成的组合疗法,作为一线疗法治疗晚期RCC患者,是继nivolumab与ipilimumab